Skip to main content
OpenTrials
Completed

NCT Number: NCT03690401

Body Composition Post Cancer Treatment

The purpose of this study is to assess how bone density and body composition changes after a cancer patient completes treatment and through 12-weeks post-treatment. Patients who enroll in the 12-week exercise program, Moving On, and those that do not elect to participate in the Moving On program will both be tracked, with assessments including SOZO measurements, DEXA scan (bone density and whole body composition), performance status tests, food log, urine color test, and other study assessments.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Cancer Neoplasms

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Prisma Health Cancer Institute Center for Integrative Oncology and Survivorship

Greenville, South Carolina, 29605, United States

About this study

This is an observational, prospective, parallel-arm device use study. 50 subjects will be enrolled in the study. The study will look at the changes in the participants body composition post cancer treatment using the SOZO device. The SOZO device is intended to estimate the following body composition parameters: Fluid status (TBW, ECF, ICF), Total body composition (fat free mass, fat mass, % of weight), Metabolic report (active tissue mass, extracellular mass, basal metabolic rate), Skeletal muscle mass, Phase angle, Body mass index (BMI), Weight, and Hydration index (Hy-Dex) analysis. Participants will have 5 study visits during 12 weeks where SOZO measurements will be taken as well as other study measurements.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Willingness and ability to provide consent
  • Mentally and physically able to comply with protocol
  • Age 18 and over
  • Body Mass Index (BMI) ≤ 40 or body weight of <300 pounds
  • Recent diagnosis of first cancer stage I-III
  • Completion of final primary cancer treatment within 6 months of Screening/Baseline visit

Exclusion criteria

  • Active implanted medical device (cardiac pacemakers, defibrillators) or connected to electronic life support devices or patients with other metallic devices that would interfere with BIS measurements
  • Amputees
  • Any acute swelling condition diagnosed or actively being treated within 30 days of screening/baseline (including, but not limited to: acute heart failure, renal disease with dialysis, pulmonary edema, thrombophlebitis, deep vein thrombosis, pleural effusion, ascites, pregnancy)
  • Patients with basal cell carcinoma or squamous cell skin cancer
  • Patients with head or neck cancer
  • Currently suffering from uncontrolled intercurrent illness, including: ongoing/active infection, unstable angina pectoris, or cardiac arrhythmia
  • Enrollment of female breast cancer patients not to exceed 60% of total projected enrollment. Once this threshold has been reached, these subjects will be excluded
  • Planned orthopedic implant surgery
  • Planned breast implant surgery
  • Presence of or plan for breast expanders post-mastectomy
  • Dependent upon transfusions
  • Any history of organ transplant
  • Presence of colostomy/ostomy

Treatment and study plan

SOZO device

Device

SOZO device will estimate fluid status, total body composition, metabolic report, skeletal muscle mass, phase angle, body mass index, weight, and hydration index analysis. Participants will be asked to fast for at least 8 hours before each visit, but water may be consumed to ensure they are well-hydrated. Participants will be asked to provide a urine sample at each visit and to report the color of your urine to the staff so they can determine how well hydrated the participants are. If not hydrated to the extent needed, participants will be asked to drink water and repeat the urine sample again after 30 minutes. A total of 5 SOZO measurements will be recorded over 12 weeks.

DEXA Scan

Device

DEXA scan bone density reading with hip and spine measurements as well as a whole body composition scan will be performed. Where DEXA cannot be collected on the same day as other study assessments, Weight/BMI, Urine Color, and SOZO should all be collected (or repeated if already done) to coincide with the DEXA scan if SOZO is available at DEXA location.

Primary outcomes

  1. SOZO device can detect changes in body composition using SOZO measurements.

    Time frame: 12 weeks

    Change from baseline in body composition measures (intracellular fluid, extracellular fluid, fat mass, fat free mass, skeletal muscle mass, phase angle, and hydration index)

Secondary outcomes

  1. Patient general health

    Time frame: 12 weeks

    Evaluate patient general health using physical performance tests

  2. Correlate SOZO with food recall.

    Time frame: 12 weeks

    Assess correlation of SOZO measurements with 3-day food recall.

  3. Correlate SOZO with DEXA Scan

    Time frame: 12 weeks

    Assess correlation of SOZO measurements and DEXA scan (bone density with hip and spine measurements and whole body composition) results.

  4. Correlate SOZO with standard of care

    Time frame: 12 weeks

    Assess correlation of SOZO measurements with standard of care measurements.

  5. Detect changes in participant fatigue

    Time frame: 12 weeks

    Change from baseline in Brief Fatigue Inventory score

  6. Detect changes in participant stress

    Time frame: 12 weeks

    Change from baseline in Suscro Distress Inventory score

  7. Correlate SOZO with urine test.

    Time frame: 12 weeks

    Assess correlation of SOZO measurements with urine color test.

Sponsors and collaborators

Lead sponsor

Prisma Health-Upstate

Other

Collaborators

  • ImpediMed Limited

Registry information

Official study title

Assessment of Body Composition in Cancer Patients Post-Treatment Using the SOZO Device

Acronym: PostSOZO

Important dates

Study start
2018
Primary completion
2023
Study completion
2023
First posted
Oct 1, 2018
Registry last updated
Oct 28, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.